The reduction in the median recovery time was approximately one day for the patient population, according to a statement. The study also met a key secondary endpoint comparing patient outcomes at Day 15 ranging from fully recovered to death.
Based on this data, which was released in conjunction with Incyte (INCY), Lilly plans to discuss a potential emergency use authorization with the US Food and Drug Administration and to explore similar options with other regulatory agencies such as Health Canada.
"If authorized for use in Canada, Lilly will propose that baricitinib be available through commercial channels and will work with hospitals and governments to ensure patient access," the company said.
Price: 152.07, Change: +1.11, Percent Change: +0.74
|Significant Insider Sales Reported in Shares of KalV...|
|Insider Sale at Mastercard (MA) Continues Selling Trend|
|Insider Selling at Illumina (ILMN) Continues with Si...|
|Insider Selling in Salesforce.com (CRM) Shares Conti...|
|VeriSign (VRSN) sees Significant Insider Sales Exten...|